NCT06513013

Brief Summary

The aim of this study is to compare the duration of analgesia obtained by addition of Neostigmine versus MgSO4 as adjuvants to bupivacaine in TAP block in patients undergoing Cesarean Section and to evaluate postoperative analgesic requirements, side effects and level of patient satisfaction.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
68

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Dec 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 20, 2023

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

July 4, 2024

Completed
18 days until next milestone

First Posted

Study publicly available on registry

July 22, 2024

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 18, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 18, 2026

Completed
Last Updated

March 31, 2026

Status Verified

March 1, 2026

Enrollment Period

2.1 years

First QC Date

July 4, 2024

Last Update Submit

March 28, 2026

Conditions

Keywords

TAPmg sulphate

Outcome Measures

Primary Outcomes (1)

  • comparasion of Postoperative NRS score for 24 hours between the two groups

    NRS Score: used to assess pain intensity (13). It is one of the most commonly used pain scales in medicine. The NRS consists of a numeric version of the visual analog scale. It is a horizontal line with an eleven point numeric range. It is labeled from zero to ten, with zero being an example of someone with no pain and ten being the worst pain possible (Figure 2). This scale can be administered verbally. Rescue analgesia will be nalbuphine 0.1 mg/kg IV when the NRS ≥ 4.

    24 hours postoperative

Secondary Outcomes (5)

  • postoperative hemodynamic parameters

    24 hours postoperative

  • time required for the first rescue analgesia

    24 hours postoperative

  • total amount of rescue analgesic consumption duringfirst 24 hours postoperatively

    24 hours postoperative

  • patient satisfacation score

    24 hours postoperative

  • PONV intensity by postoperatively:

    24 hours postoperative

Study Arms (2)

Group M "bupivacaine + normal saline + MgSO4"

ACTIVE COMPARATOR

will receive 25 ml volume on each side ( 20 ml of 0.25% bupivacaine plus 5 ml of normal saline containing 250 mg of MgSO4 )

Procedure: transversus abdominis plane (TAP) block in cesarean sectionDrug: Magnesium sulfate

Group D "bupivacaine + normal saline + Neostigmine"

ACTIVE COMPARATOR

will receive 25 ml volume on each side ( 20 ml of 0.25% bupivacaine plus 5 ml of normal saline containing 500 mcg of Neostigmine

Procedure: transversus abdominis plane (TAP) block in cesarean sectionDrug: Neostigmine

Interventions

.an intravenous (IV) access will be secured . Standard ASA monitoring will be instituted which include(SpO2), ECG and (NIBP) . At the end of surgery , a bilateral USG-guided TAP block will be carried out under strict aseptic precautions, and 20 mL of study solution was injected into each side. After draping the abdominal region between the 12th rib and anterior superior iliac crest with the umbilicus in the center, the external oblique muscle, internal oblique muscle, transversus abdominis muscle , and their fascia will be located beneath the skin and subcutaneous tissue using a linear high-frequency probe 6-13 Megahertz of the SonoSite Micromax machine. A 22-gauge spinal needle will be advanced using the in-plane technique at the anterior axillary line, and the precise position of the needle tip between the internal oblique and transverse abdominis muscle will be visualized. To expand the plane, 2 mL of normal saline will be administered.

Group D "bupivacaine + normal saline + Neostigmine"Group M "bupivacaine + normal saline + MgSO4"

25ml volume on each side (20ml of 0.25% bupivacaine plus 5ml of normal saline containing 250 mg of MgSO4) to keep the total volume the same in both group

Group M "bupivacaine + normal saline + MgSO4"

25ml volume on each side (20ml of 0.25% bupivacaine plus 5ml of normal saline containing 500 mcg neostigmine. A 22-gauge spinal needle will be advanced using the in-plane technique at the anterior axillary line, and the precise position of the needle tip between the internal oblique and transverse abdominis muscle will be visualized. To expand the plane, 2 mL of normal saline will be administered. Following the affirmation of a hypoechoic region on the USG image, the study solutions will be injected as per group allocation. Postoperatively,both groups of patients received an injection of paracetamol 1gm intravenously every 8th hourly as a part of multimodal analgesia and the patients will be evaluated for pain, nausea or vomiting in the post anaesthesia care unit at time 0 (time of completion of TAP block), 2, 4, 6,12 and 24 h by an investigator blinded to the group assignment. Whenever the NRS \>4, Nalbuphine 0.1 mg/kg IV will be administered as a rescue analgesic.

Group D "bupivacaine + normal saline + Neostigmine"

Eligibility Criteria

Age19 Years - 40 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age from 19 to 40 years old
  • Singleton pregnencies with a gestational age of at least 37 weeks
  • American society of anesthesiologists (ASA) physical state I , II
  • patients undergoing spinal anesthesia for cesarean delivery via Pfannenstiel incision with exteriorization of the uterus.

You may not qualify if:

  • Patient's refusal
  • Age \< 19 or \> 40 years
  • Height\<150 cm, weight \< 60 kg, body mass index (BMI) ≥40 kg/m2.
  • Contraindications to spinal anesthesia (Coagulopathy, increased intracranial pressure, or local skin infection).
  • Cardio-respiratory conditions
  • Convulsions
  • Inability to comprehend or participate in the pain scoring system.
  • Bleeding diathesis
  • Known allergy to any drugs used in this study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Women's Health Hospital, Assiut University

Asyut, Egypt

Location

Related Publications (3)

  • Kapral S, Gollmann G, Waltl B, Likar R, Sladen RN, Weinstabl C, Lehofer F. Tramadol added to mepivacaine prolongs the duration of an axillary brachial plexus blockade. Anesth Analg. 1999 Apr;88(4):853-6. doi: 10.1097/00000539-199904000-00032.

    PMID: 10195537BACKGROUND
  • Verma K, Malawat A, Jethava D, Jethava DD. Comparison of transversus abdominis plane block and quadratus lumborum block for post-caesarean section analgesia: A randomised clinical trial. Indian J Anaesth. 2019 Oct;63(10):820-826. doi: 10.4103/ija.IJA_61_19. Epub 2019 Oct 10.

    PMID: 31649394BACKGROUND
  • Abrahams MS, Horn JL, Noles LM, Aziz MF. Evidence-based medicine: ultrasound guidance for truncal blocks. Reg Anesth Pain Med. 2010 Mar-Apr;35(2 Suppl):S36-42. doi: 10.1097/AAP.0b013e3181d32841.

    PMID: 20216023BACKGROUND

MeSH Terms

Interventions

Dental OcclusionCesarean SectionMagnesium SulfateNeostigmine

Intervention Hierarchy (Ancestors)

DentistryDental Physiological PhenomenaDigestive System and Oral Physiological PhenomenaDelivery, ObstetricObstetric Surgical ProceduresSurgical Procedures, OperativeMagnesium CompoundsInorganic ChemicalsSulfatesSulfuric AcidsSulfur AcidsSulfur CompoundsPhenylammonium CompoundsQuaternary Ammonium CompoundsAminesOrganic ChemicalsOnium Compounds

Study Officials

  • Zain Alabdin Zaree Hassan

    Assiut University

    STUDY CHAIR
  • Nashwa Farouk Abdel Hafez

    Assiut University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
resident

Study Record Dates

First Submitted

July 4, 2024

First Posted

July 22, 2024

Study Start

December 20, 2023

Primary Completion

January 18, 2026

Study Completion

January 18, 2026

Last Updated

March 31, 2026

Record last verified: 2026-03

Locations